Is Rhythm Pharmaceuticals, Inc. (RYTM) Stock Poised for Growth After Encouraging Setmelanotide Trial Results?
TheFly reported on June 16 that Canaccord analyst Whitney Ijem increased the price target on RYTM to $151 from $143 while maintaining a Buy rating.







